Tolterodine
Tolterodine is a pharmaceutical drug with 38 clinical trials. Currently 1 active trials ongoing. Historical success rate of 93.9%.
Success Metrics
Based on 31 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
9
Mid Stage
18
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
91.2%
31 of 34 finished
8.8%
3 ended early
1
trials recruiting
38
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Treatment of Overactive Bladder With Anticholinergic Agents
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
Clinical Trials (38)
Treatment of Overactive Bladder With Anticholinergic Agents
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
Pharmacological vs Surgical Treatment for Mixed Incontinence
Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study
Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
Genetic Determinants of Amitriptyline Efficiency for Pain Treatment
Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part II
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery
SSR240600C Treatment in Women With Overactive Bladder
Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)
Study of Herbmed Plus in Ureteral Stent Discomfort
Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects
The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 38